58997-10-7

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-METHYLPYRIDINE-2-CARBOXYLATE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its presence in the industry is crucial for the development of new drugs and the improvement of existing ones.
Used in Chemical Synthesis:
ETHYL 3-METHYLPYRIDINE-2-CARBOXYLATE is used as a starting material or a building block in the synthesis of other organic compounds. Its versatility in chemical reactions makes it a valuable component in the creation of a wide range of chemical products.
Used in Research and Development:
ETHYL 3-METHYLPYRIDINE-2-CARBOXYLATE is used as a research compound in academic and industrial laboratories. It serves as a test subject for studying chemical reactions, properties, and potential applications in various fields, including materials science and biotechnology.

InChI:InChI=1/C9H11NO2/c1-3-12-9(11)8-7(2)5-4-6-10-8/h4-6H,3H2,1-2H3

Upstream product

• 4021-07-2 3-methyl-pyridine-2-carboxylic acid 
• 64-17-5 ethanol 
• 1003-73-2 3-picoline-N-oxide 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 94015-06-2 ethyl 3-chloromethylpyridine-2-carboxylate 
• 301666-61-5 ethyl 3-(bromomethyl)pyridine-2-carboxylate 
• 1201924-32-4 6-chloro-3-methyl-pyridine-2-carboxylic acid 
• 1211584-54-1 5,6-dihydro-pyrrolo[3,4-b]pyridin-7-one 
• 301666-62-6 ethyl 3-(cyanomethyl)picolinate 
• 1392842-80-6 3-[(1-benzyl-5-hydroxy-2-oxo-3-phenyl-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid 
• 1392842-66-8 3-[(1-benzyl-8-hydroxy-5-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-propionic acid 
• 1392839-57-4 1-benzyl-8-hydroxy-5-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid methyl ester 
• 1392842-63-5 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide 
• 1392842-50-0 1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide 
• 1392842-46-4 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid [2-(methanesulfonyl-methyl-amino)-ethyl]-amide 
• 1392842-33-9 1-benzyl-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-acetylamino-ethyl)-amide 
• 1392842-32-8 1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carboxylic acid (2-acetylamino-ethyl)-amide 
• 1392842-31-7 3-[(1-benzyl-5-cyano-8-hydroxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-7-carbonyl)-amino]-propionic acid 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

Noncovalent Interactions in Ir-Catalyzed C-H Activation: L-Shaped Ligand for Para-Selective Borylation of Aromatic Esters

An efficient strategy for the para-selective borylation of aromatic esters is described. For achieving high para-selectivity, a new catalytic system has been developed modifying the core structure of the bipyridine. It has been proposed that the L-shaped ligand is essential to recognize the functionality of the oxygen atom of the ester carbonyl group via noncovalent interaction, which provides an unprecedented controlling factor for para-selective C-H activation/borylation.

NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS

The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.

DIMETHYLBENZOIC ACID COMPOUNDS

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.

NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE

The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives

Excessive calpain activation contributes to serious cellular damage in many pathological conditions. The involvement of μ-calpain in neurological disorders such as, stroke and Alzheimer's disease has attracted considerable interest in the use of calpain i

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.

Preparation of some Thiopyranopyridine Derivatives

In the first systematic study of thiopyranopyridines in which the sulphur atom is separated from the pyridine ring by one carbon atom, the four isomeric enol esters, ethyl 5-hydroxy-8H-thiopyranopyridine-6-carboxylate (4b), ethyl 8-hydroxy-5H-thiopyranopyridine-7-carboxylate (5b), and ethyl 4-hydroxy-1H-thiopyrano- and pyridine-3-carboxylate (6b) and (7b), have been synthesised.Improved methods for the preparation of their pyridine precursors are described.With phenylhydrazine, the enol esters (4b) - (7b) give condensed pyrazole derivatives (15) - (18), which have dipolar structures; with hot mineral acid they undergo decarboxylative hydrolysis, to give the corresponding oxothiopyranopyridines (4a) - (7a).